Literature DB >> 28857827

Injecting drug use predicts active tuberculosis in a national cohort of people living with HIV.

Joanne R Winter1, Helen R Stagg, Colette J Smith, Alison E Brown, Maeve K Lalor, Marc Lipman, Anton Pozniak, Andrew Skingsley, Peter Kirwan, Zheng Yin, H Lucy Thomas, Valerie Delpech, Ibrahim Abubakar.   

Abstract

OBJECTIVES: Tuberculosis (TB) is common in people living with HIV, leading to worse clinical outcomes including increased mortality. We investigated risk factors for developing TB following HIV diagnosis.
DESIGN: Adults aged at least 15 years first presenting to health services for HIV care in England, Wales or Northern Ireland from 2000 to 2014 were identified from national HIV surveillance data and linked to TB surveillance data.
METHODS: We calculated incidence rates for TB occurring more than 91 days after HIV diagnosis and investigated risk factors using multivariable Poisson regression.
RESULTS: A total of 95 003 adults diagnosed with HIV were followed for 635 591 person-years; overall incidence of TB was 344 per 100 000 person-years (95% confidence interval 330-359). TB incidence was high for people who acquired HIV through injecting drugs [PWID; men 876 (696-1104), women 605 (365-945)] and black Africans born in high TB incidence countries [644 (612-677)]. The adjusted incidence rate ratio for TB amongst PWID was 4.79 (3.35-6.85) for men and 6.18 (3.49-10.93) for women, compared with MSM. The adjusted incidence rate ratio for TB in black Africans from high-TB countries was 4.27 (3.42-5.33), compared with white UK-born individuals. Lower time-updated CD4 cell count was associated with increased rates of TB.
CONCLUSION: PWID had the greatest risk of TB; incidence rates were comparable with those in black Africans from high TB incidence countries. Most TB cases in PWID were UK-born, and likely acquired TB through transmission within the United Kingdom. Earlier HIV diagnosis and quicker initiation of antiretroviral therapy should reduce TB incidence in these populations.

Entities:  

Mesh:

Year:  2017        PMID: 28857827     DOI: 10.1097/QAD.0000000000001635

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  4 in total

1.  HIV treatment outcomes among people who acquired HIV via injecting drug use in the Asia-Pacific region: a longitudinal cohort study.

Authors:  Win Min Han; Awachana Jiamsakul; Nur Afiqah Mohd Salleh; Jun Yong Choi; Bui Vu Huy; Evy Yunihastuti; Cuong Duy Do; Tuti P Merati; Yasmin M Gani; Sasisopin Kiertiburanakul; Fujie Zhang; Yu-Jiun Chan; Man-Po Lee; Romanee Chaiwarith; Oon Tek Ng; Suwimon Khusuwan; Rossana Ditangco; Nagalingeswaran Kumarasamy; Shashikala Sangle; Jeremy Ross; Anchalee Avihingsanon
Journal:  J Int AIDS Soc       Date:  2021-05       Impact factor: 6.707

2.  Changing Spectrum of Opportunistic Illnesses among HIV-Infected Taiwanese Patients in Response to a 10-Year National Anti-TB Programme.

Authors:  Chun-Yuan Lee; Pei-Hua Wu; Po-Liang Lu; Hung-Chin Tsai
Journal:  J Clin Med       Date:  2019-02-01       Impact factor: 4.241

3.  Trends in, and factors associated with, HIV infection amongst tuberculosis patients in the era of anti-retroviral therapy: a retrospective study in England, Wales and Northern Ireland.

Authors:  Joanne R Winter; Helen R Stagg; Colette J Smith; Maeve K Lalor; Jennifer A Davidson; Alison E Brown; James Brown; Dominik Zenner; Marc Lipman; Anton Pozniak; Ibrahim Abubakar; Valerie Delpech
Journal:  BMC Med       Date:  2018-06-07       Impact factor: 8.775

4.  Alarming Tuberculosis Rate Among People Who Inject Drugs in Vietnam.

Authors:  Nicolas Nagot; Vinh Vu Hai; Thuy Thi Thu Dong; Oanh Khuat Thi Hai; Delphine Rapoud; Giang Thi Hoang; Catherine Quillet; Khue Pham Minh; Roselyne Vallo; Thanh Tuyet Thi Nham; Joëlle Castellani; Jonathan Feelemyer; Don C Des Jarlais; Lan Phuong Nguyen; Hoi Van Le; Nhung Viet Nguyen; Luan Nguyen Quang Vo; Huong Thi Duong; Jean-Pierre Moles; Didier Laureillard
Journal:  Open Forum Infect Dis       Date:  2021-11-08       Impact factor: 3.835

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.